Head-to-head · WeighScore
Cielo vs RxPepsDirect
The verdict
Cielo takes it — 69.4/100 to 68.7/100, but only just.
Cielo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cielo is a compounded-GLP-1-only telehealth platform offering semaglutide and tirzepatide with no brand-name drugs and no TRT, hair, or mental-health add-ons — a focused, single-purpose alternative to… RxPepsDirect is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cielo | RxPepsDirect |
|---|---|---|
| WeighScore | 69.4/100 | 68.7/100 |
| Grade | C | C |
| Scorecard rank | #121 | #140 |
| Semaglutide | $149/mo (all doses, compounded) | $79/mo (starting dose, visit fee and shipping included, compounded) |
| Tirzepatide | $249/mo (all doses, compounded) | $99/mo (starting dose, visit fee and shipping included, compounded) |
| Coverage | Coverage not published | 28 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #121 · C
Strengths
- Among the lowest 3-month bundle prices in compounded GLP-1 ($115/mo semaglutide)
- Single flat price across all doses simplifies titration planning
- Corporate address (St. Petersburg, FL) and customer-service phone published
Where it loses points
- No LegitScript, NABP .pharmacy, or HIPAA badge on the home page
- Pharmacy partner not named (only 'regulated FDA pharmacy partners')
- State coverage list not published — can't verify all-50-state availability
- Clinical care runs through MD Integrations, a shared third-party network used by many brands
- No brand-name Wegovy or Zepbound option
Graded #140 · C
Strengths
- Every component of the price is published on the site — the vial tiers, the flat visit charge and the flat overnight delivery — so the all-in monthly cost can be worked out before ordering
- No subscription and no commitment: you pay per order, and one visit charge covers up to three peptides on the same prescription
- Real 503A telehealth Rx — licensed NP/PA prescribers under medical director Dr. Jonathan Snipes (NPI 1821250077), dispensed by Optimal Balance Pharmacy, Texas Board #34829
- Independent batch COA testing by Eagle Analytical (FDA-registered, A2LA ISO 17025): 54/54 sterility and endotoxin passes published publicly
- Ships pre-reconstituted by FedEx overnight with syringes, alcohol wipes and a reusable cooled travel case included
Where it loses points
- The advertised vial price is not the monthly cost: a flat $39 medical visit charge and $15 flat FedEx shipping land on every order, and the visit charge recurs on every reorder rather than once
- Higher doses need more than one vial a month and the site publishes no price for the dose you titrate up to, so the figure above is a floor
- Minimal clinical oversight: a roughly two-minute asynchronous intake, no live video consult, no labs required and no published dose-escalation monitoring
- No LegitScript certification, and the company was founded in 2026 with no public track record or outcomes data
- Only 28 states and DC — California is excluded, along with most of the Southeast (AL, AR, GA, MS, NC, SC, TN, VA)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.